Life Science Unit of Merck KGaA Sees 30.7% Q3 EBITDA Growth
German multinational science and technology company Merck KGaA announced its Life Science unit, which supplies tools and materials for the
Read more
Latest
Japan to Buy 1.6 Mill Courses of Merck’s Oral COVID-19 Antiviral Molnupiravir
Merck (MRK) and Ridgeback Biotherapeutics have announced that the Japanese government will acquire approximately 1.6 million courses of molnupiravir (MK-4482,
Read more
J&J to Provide its One Dose COVID-19 Vaccine to the Most Vulnerable via COVAX Humanitarian Buffer
The world’s most vulnerable populations are given access to COVID-19 vaccines thanks to the COVAX Humanitarian Buffer. Johnson & Johnson
Read more
Pfizer’s COVID-19 Oral Antiviral Candidate 89% Effective in Phase 2/3 Study
The novel COVID-19 investigational oral antiviral treatment PAXLOVID™ (PF-07321332; ritonavir) by Pfizer, was found to reduce the risk of hospitalization
Read more
First Oral COVID-19 Antiviral Medicine Approved in the UK
Merck and Ridgeback’s Molnupiravir has become the world’s first approved oral COVID-19 antiviral drug. Molnupiravir has been authorised by the
Read more
SCIEX and Evosep Collaborate to Enhance High-Throughput Proteomics
SCIEX and Evosep have established a collaboration to co-market solutions designed to enhance the stability of high-throughput proteomics systems for
Read more
Agilent’s PD-L1 IHC 22C3 pharmDx Assay Approved for TNBC use in EU
Agilent’s PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying Triple-Negative Breast Cancer (TNBC) patients for
Read more
First Evotec-BMS Academic BRIDGE Collaboration Projects to Focus on Oncology
The first two projects funded within the translational BRIDGE beLAB1407 collaboration will focus on new mechanisms to treat cancer, Evotec
Read more
FDA Panel in Favor of Pfizer’s COVID-19 Vaccine for Children Aged 5 to 12
The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0,
Read more
Valneva’s COVID-19 Vaccine Candidate Shows Positive Results in Phase 3 Trial
French pharmaceutical company Valneva has reported positive results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 in the Phase 3
Read more